Please assess the completion status of the following clinical trial:

Trial Title: ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* newborns and infants with weight lower than 10 kg undergoing cardiac surgery with extracorporeal circulation:~* informed consent signed by both parents or legal guardian.~Exclusion Criteria:~* emergency surgery;~* known congenital coagulopathy or suspected based on anamnesis;~* participation to other clinical trials;~* known hypersensitivity to components and excipients of FFP , prothrombin complex concentrate or fibrinogen concentrate.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 2 Years
- Healthy Volunteers: f

Study Arms:
- ZEPLAST (Type: EXPERIMENTAL): In case of bleeding and:~* CT INTEM \> CT HEPTEM by 25% : give protamine 0.25 mg/kg;~* MCF FIBTEM \< 8 mm : give Fibrinogen Concentrate 30 mg/kg;~* CT EXTEM \> 100 s : give Prothrombin Complex Concentrate 20 mg/kg.
- Control (Type: ACTIVE_COMPARATOR): In case of bleeding and:~* CT INTEM \> CT HEPTEM by 25% : give protamine 0.25 mg/kg;~* fibrinogen and/or thrombin generation deficiency : give FFP 10-20 ml/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).